Companies/Avita Medical Inc.

Company profile

Avita Medical Inc.

NASDAQ: RCEL · Healthcare · Medical - Devices

PublicHQ Valencia, CACIK 0001762303Reports USD

#385 of 1,394 Healthcare companies by revenue57th-percentile growth

EA Score

50D

FH 45DQ 50GM 59SS 67

v0.1 · 65/100 weight · provisional

↑ workforce scale, 3-yr revenue growth · ↓ balance-sheet leverage, disclosure history

Methodology →

Revenue TTM

$72.3M

Rev growth YoY (TTM)

+1.0%

Net income (FY)

-$48.6M

Employees

232

Market cap

$125.7M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$70.9M$70.9M2025

Net income-$48.6M-$48.6M2025

Operating income-$42.5M-$42.5M2025

Total assets$56.4M$56.4M2025

Liabilities$73.0M$73.0M2025

Equity-$16.6M-$16.6M2025

Revenue trend

FY2021 – FY2025 · USD

$10.2M

FY21

$8.8M

FY21

$29.2M

FY21

$14.0M

FY21

$34.4M

FY22

$50.1M

FY24

$63.9M

FY24

$70.9M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Lease Revenue100%

By geography

UNITED STATES97%

JAPAN3%

AUSTRALIA0%

European Union0%

The read

Avita Medical Inc. booked $70.9M in FY2025 revenue, growing 11% year over year — about the middle of the pack among Healthcare companies we track, at a -68.5% net margin.

Peers · Healthcare

Aardvark Therapeutics, Inc. Common Stock40D Spero Therapeutics, Inc.68B The Joint Corp.75B+Unicycive Therapeutics, Inc.31D

Key facts

CEOCary G. Vance

SectorHealthcare

IndustryMedical - Devices

HeadquartersValencia, CA

ExchangeNASDAQ: RCEL

Employees232

IPO date2012-05-14

Latest filings

8-K2026-06-08 8-K2026-06-04 10-Q2026-05-14 8-K2026-05-14 8-K2026-05-01 DEF 14A2026-04-22 8-K2026-02-12 10-K2026-02-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.